Proton Pump Inhibitors and Infant Pneumonia/Other Lower Respiratory Tract Infections: National Nested Case-control Study
Abstract
T o the Editor: Few studies have examined the association between the use of proton pump inhibitors and infant pneumonia/other lower respiratory tract infections acquired in the community (1,2); hence, the importance of the work by Blank et al (3), who in a national nested case-control study, failed to demonstrate this possible association. Despite of the multiple strengths of their study, for a better comprehension of the article, it would have been interesting to know variables such as gestational age; birth weight of the children; feeding antecedents related to breastfeeding, infant formulas, and complementary feeding; any alimentary allergy; and the use of special infantile formulas for said allergies. In addition, knowledge of vaccines other than pneumococcal conjugate vaccine, an analysis of the weather stations, and epidemics caused by a respiratory virus that affected these children during the study were also necessary. Finally, to perform a subanalysis, it was necessary to know the dose and the type of proton pump inhibitor indicated in terms of omeprazole, lansoprazole, or pantoprazole.
How strong is the evidence?
Evidence Hub reads this as a case-control, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause.
Read the paper
Related studies
- The Prediction of the In Vitro Release Curves for PLGA-Based Drug Delivery Systems with Neural Networks
- Promising Ursolic Acid as a Novel Antituberculosis Agent: Current Progress and Challenges
- Proof of principle concept for the analysis and functional prediction of rare genetic variants in the CYP2C19 and CYP2D6 genes
- Fabrication, characterization, and docking studies of furosemide-loaded nanosponges using the emulsion solvent diffusion method
- The Effect of Concomitant Administration of Proton Pump Inhibitors on the Pharmacokinetics of CDK4/6 Inhibitors in Rats: Implications for the Evaluation of Hepatic and Transporter-Mediated Drug–Drug Interactions
- Mining the Metabolic Capacity of Clostridium sporogenes Aided by Machine Learning
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.